Drugs / OST31-164
last change Sep 2023 re-read 3 minutes ago

OST31-164

Developed for
bone cancer
Investigated by
Emerald Clinical Inc.

Trials 1

20222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT04974008 Oct 2021 → Sep 2023 overdue bone cancer Emerald Clinical Inc. Active not recruiting No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as OST31-164 ClinicalTrials.gov intervention name — accepted as the source's own label NCT04974008 ↗